|Bid||0.00 x 1400|
|Ask||0.00 x 29200|
|Day's Range||35.54 - 35.92|
|52 Week Range||31.67 - 39.43|
|PE Ratio (TTM)||9.91|
|Forward Dividend & Yield||1.36 (3.82%)|
|1y Target Est||N/A|
LONDON, UK / ACCESSWIRE / May 24, 2018 / If you want access to our free research report on Spark Therapeutics, Inc. (NASDAQ: ONCE), all you need to do is sign up now by clicking the following link www.active-investors.com/registration-sg/?symbol=ONCE as the Company's latest news hit the wire. On May 22, 2018, Spark Therapeutics and Pfizer Inc. announced that it has presented encouraging results from ongoing Phase-1/2 clinical trial assessing investigational SPK-9001 for severe or moderately severe hemophilia B, at the World Federation of Hemophilia (WFH) World Congress in Glasgow, Scotland. All 15 participants in the clinical trial followed for 5 to 121 weeks had discontinued routine infusions of factor IX concentrates.
Pfizer Inc. announced today that tafamidis received Breakthrough Therapy designation from the US Food and Drug Administration for the treatment of patients with tr
Pfizer Inc. announced today that results from a study analyzing real-world effectiveness data found that Prevnar 13® reduced the risk of hospitalization from vaccine-type pneumococcal community-acquired pneumonia by 73% in adults aged 65 and older.1 Importantly, Prevnar 13 worked under real-world conditions where people received pneumococcal vaccination as advised by their health care providers, and ...
Pfizer Inc. (PFE) today announced that it has started a Phase 1/2 trial of its respiratory syncytial virus (RSV) vaccine candidate in healthy adult volunteers. RSV is a common respiratory virus that affects the lungs and airways, with significant impact on young children and older adults.
Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (PFE), today announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe (FIX:C
Spark Therapeutics (ONCE), a fully integrated gene therapy company dedicated to challenging the inevitability of genetic disease, and Pfizer (PFE), today announced that, with a cumulative follow-up of more than 18 patient years of observation (5 to 121 weeks), all 15 participants in the ongoing Phase 1/2 clinical trial of investigational SPK-9001 for severe or moderately severe (FIX:C ≤ 2 percent) hemophilia B, had discontinued routine infusions of factor IX concentrates. None of the 15 participants experienced serious adverse events, and there were no thrombotic events or factor IX inhibitors, as of the May 7, 2018 data cutoff.
ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Comm
Invacare Corporation (IVC) today announced the appointment of Petra Danielsohn-Weil, PhD, to its Board of Directors, effective May 17, 2018. From 2014 until her retirement in August 2017, Ms. Danielsohn-Weil was the Regional President for Pfizer Essential Health - Europe, a leader in non-viral anti-infectives, biosimilars and sterile injectable medicines and a unit of Pfizer Inc. (PFE), a research-based, global biopharmaceutical company.
Pfizer Inc. announced today positive top-line results of a Phase 3 study examining the use of LYRICA® Oral Solution CV as adjunctive therapy for partial onset seizures in pediatric epilepsy patients one month to less than four years of age.
Pfizer Inc. today announced that new data from its diversified portfolio of marketed and investigational oncology medicines will be presented at the 54th Annual Meeting of the American Society of Clinical Oncology in Chicago from June 1-5, 2018.
Pfizer Inc. (PFE) today announced the United States (U.S.) Food and Drug Administration (FDA) approved RETACRIT® (epoetin alfa-epbx), a biosimilar to Epogen® and Procrit® (epoetin alfa)1, for all indications of the reference product. RETACRIT is now the first and only biosimilar erythropoiesis-stimulating agent (ESA) to be approved in the U.S. “As the first approved epoetin alfa biosimilar in the U.S., RETACRIT may provide patients and their physicians with increased access to a high-quality, lower-cost alternative treatment option for anemia and the reduction of allogeneic red blood cell (RBC) transfusions in certain patients,” said Berk Gurdogan, U.S. Institutions President, Pfizer Essential Health.
Stock Research Monitor: AZN, CPHI, and MRK LONDON, UK / ACCESSWIRE / May 15, 2018/ If you want a free Stock Review on PFE sign up now at www.wallstequities.com/registration . This morning, WallStEquities.com ...
Wave Life Sciences Ltd. (WVE), a biotechnology company focused on delivering transformational therapies for patients with serious, genetically-defined diseases, today announced that Pfizer (PFE) recently nominated the fourth and fifth final hepatic targets under the collaboration agreement between the two companies to develop genetically targeted therapies for the treatment of metabolic hepatic diseases, such as nonalcoholic steatohepatitis. Upon payment of nomination fees, Pfizer had the right to select a maximum of five targets to advance from discovery through candidate selection with Wave.
The board of directors of Pfizer Inc. today declared a 34-cent second-quarter 2018 dividend on the company’s common stock, payable June 1, 2018, to shareholders of record at the close of business on May 11, 2018. The second-quarter 2018 cash dividend will be the 318th consecutive quarterly dividend paid by Pfizer. “In 2017, we returned nearly $12.7 billion to shareholders through dividends and share repurchases,” said Ian Read, chairman and chief executive officer.
Pfizer Inc. (NYSE: PFE) today announced that TRUMENBA® (Meningococcal Group B Vaccine) received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for active immunization to prevent invasive disease caused by Neisseria meningitidis group B (MenB) in children ages 1 through 9 years. This is the first Breakthrough Therapy designation for a MenB vaccine to help protect children as young as 1 year of age.
Pfizer Inc. (PFE) today announced that it received a Complete Response Letter (CRL) from the United States Food and Drug Administration (FDA) in response to the Biologics License Application for the company’s proposed trastuzumab biosimilar. In the CRL, the FDA highlighted the need for additional technical information. The additional requested information does not relate to safety or clinical data submitted in the application.
Pfizer Inc. today announced that the European Commission has approved MYLOTARG™ in combination with daunorubicin and cytarabine for the treatment of patients age 15 years and above with previously untreated, de novo, CD33-positive acute myeloid leukemia , except acute promyelocytic leukemia .
Pfizer Inc. invites investors and the general public to listen to a webcast of the Annual Meeting of Shareholders at 9:00 a.m. (Eastern Daylight Time) on Thursday, April 26, 2018. To pre-register and access the live audio webcast, visit https://investors.pfizer.com/proxy and click on the “Annual Meeting Webcast” button. At Pfizer, we apply science and our global resources to bring therapies to people that extend and significantly improve their lives.
A.M. Best has affirmed the Financial Strength Rating of A and the Long-Term Issuer Credit Rating of “a+” of Blue Whale Re Ltd. . The outlook of these Credit Ratings is stable.
NEW YORK, April 16, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of ...
NEW YORK, NY / ACCESSWIRE / April 13, 2018 / Novavax shares crumbled on Thursday after the company sold 30.3 million shares of common stock to the public at a lower price than what the stock closed on ...
Pfizer Inc. has initiated a Phase 1b clinical trial for its mini-dystrophin gene therapy candidate, PF-06939926, in boys with Duchenne muscular dystrophy . The first boy received an infusion of the mini-dystrophin gene on March 22nd, administered under the supervision of principal investigator, Edward Smith, MD, Associate Professor of Pediatrics and Neurology at Duke University Medical Center.
Pfizer Inc. today announced that the independent Data Monitoring Committee for the Phase 3 ATLAS trial evaluating INLYTA® as adjuvant therapy for patients at high risk of recurrent renal cell carcinoma after nephrectomy recommended stopping the trial at a planned interim analysis due to futility.
Pfizer announced that it has signed a 20-year lease for The Spiral, an office tower being built by Tishman Speyer, at 66 Hudson Boulevard at Hudson Yards of Manhattan. As part of its 20-year lease agreement, Pfizer will relocate its global headquarters from 235 East 42nd Street to The Spiral where it will occupy 15 floors, and expects to begin moving colleagues there in 2022.